Pennsylvania · Nonprofit
PANCREATIC CANCER CURE FOUNDATION
PANCREATIC CANCER CURE FOUNDATION (Pennsylvania) receives grants from 7 organizations whose IRS filings report $67,497 to it, the largest being NETWORK FOR GOOD ($53,093). 4 of them have funded it in more than one year, and 98% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- Revenue FY2025
- $90k
- Funders on record
- 7
- Grants received
- $67k
- Net assets
- $8k
What Pancreatic Cancer Cure Foundation does
Mission
Pancreatic Cancer Cure Foundation's mission is to raise money and distribute funding primarily towards pancreatic cancer research and compassionate care initiatives, and, to a lesser extent, awareness and advocacy efforts.
As stated on its FY2025 Form 990.
Programs
$34,500 in funding was provided to sidney kimmel cancer center at jefferson university, an nci-designated facility. $32,500 of that amount was specifically directed to the pancreas, biliary & related research center to support research. The supported research includes seeking improvements to early detection of pancreatic cancer and to develop more effective screening procedures. This facility is leading investigations into genetic, environmental and lifestyle links to pancreatic and related cancers, including novel approaches to individualized therapy based on molecular genetic features of tumors. The remaining $2,000 of this funding was used for jefferson's "compassionate care" initiatives supporting pancreatic cancer patients during treatment.
$34,500 spentof which $34,500 as grants43% of program spending$31,500 was provided to fox chase institute for cancer research to be directed to the marvin & concetta greenberg pancreatic cancer institute at fox chase. This funding supports multi-disciplinary research currently being conducted in key areas, such as tumor microenvironment & fibroblast signaling, cancer metabolism, clincial trials & neoadjuvant therapy, and population sciences which analyze cultural, behavioral, genetic and environmental factors that could be used to tailor treatments and support community outreach.
$31,500 spentof which $31,500 as grants39% of program spending$10,000 was provided to uplifting athletes 2025 young investigator program providing the basis for a matching grant by the uplifting athletes organization. This matching grant basis was combined with pccf nomination of dr. Jaye gardiner for the young investigator grant selection of which only 10 recipients are selected nationally each year. The aggregate funding (pccf base and uplifting athletes match) will allow dr. Gardiner to continue the research she initiated at the marvin & concetta greenburg pancreatic cancer institute at fox chase cancer center where she focuses on the tumor microenvironment (tme) and how tme plays a key role in the growth of tumors in pancreatic adenocarcinoma.
$10,000 spentof which $10,000 as grants13% of program spending$4,000 was provided to st. Luke's cancer center for "compassionate care" distribution to financially compromised pancreatic cancer patients providing support to cover costs such as transportation, utilities, etc. During treatment.
$4,000 spentof which $4,000 as grants5% of program spending
The 4 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $80,000.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2017 to 2018, from $3k to $25k (+651%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
100% of PANCREATIC CANCER CURE FOUNDATION’s revenue is contributions — about as donation-reliant as the typical peer (100% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 4 of the last 9 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Who funds it, year by year
2018 → 2023: the base broadened from 1 funder to 2 funders, grant income rose $25 → $570.
3 of 7 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 98% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of PANCREATIC CANCER CURE FOUNDATION’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
PANCREATIC CANCER CURE FOUNDATION leans on a few funders — its largest provides 79% of grant income and the top three 98%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
98% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund PANCREATIC CANCER CURE FOUNDATION.
Largest funder’s share by year: 2018 100% · 2019 99% · 2020 98% · 2021 96% · 2022 65% · 2023 87% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Where its funders are
98% of PANCREATIC CANCER CURE FOUNDATION's grant income arrives through donor-advised or pass-through sponsors, whose addresses record where the money is held rather than where the donor is. Of the $1k that is directly attributable, 91% of it comes from Pennsylvania funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $66k arriving through sponsors registered in 2 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
PANCREATIC CANCER CURE FOUNDATION has grown faster than three-quarters of the 6,360 health nonprofits its size.
this organization peer median middle 50% of peers· 6,360 health nonprofits under $100k, FY2025
Organizations like PANCREATIC CANCER CURE FOUNDATION
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Pennsylvania
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
91% of spending goes to programs.
Governance
Public support
92%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Screen this organization
A dated, signed PDF of the compliance screen for PANCREATIC CANCER CURE FOUNDATION: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds PANCREATIC CANCER CURE FOUNDATION?
- PANCREATIC CANCER CURE FOUNDATION (Pennsylvania) receives grants from 7 organizations whose IRS filings report $67,497 to it, the largest being NETWORK FOR GOOD ($53,093). 4 of them have funded it in more than one year, and 98% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- How many funders does PANCREATIC CANCER CURE FOUNDATION have?
- IRS filings report 7 organizations giving $67,497 in grants to PANCREATIC CANCER CURE FOUNDATION, 4 of which have funded it in more than one year.
- Who is the largest funder of PANCREATIC CANCER CURE FOUNDATION?
- NETWORK FOR GOOD is the largest funder on record, with $53,093 in grants. The full list of funders is on this page.
- How can an organization like PANCREATIC CANCER CURE FOUNDATION find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Pennsylvania. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2017–2025), and the filings of 7 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing